Fostemsavir Tromethamine
Brand name: Rukobia
Rank #357 of 500 drugs by total cost
$27.8M
Total Cost
3,094
Total Claims
$27.8M
Total Cost
156
Prescribers
$8,970
Cost per Claim
53
Beneficiaries
3,125
30-Day Fills
$178K
Avg Cost/Provider
20
Avg Claims/Provider
About Fostemsavir Tromethamine
Fostemsavir Tromethamine (sold as Rukobia) was prescribed 3,094 times by 156 Medicare Part D providers in 2023, costing the program $27.8M. At $8,970 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 354 | Interferon Beta-1b (Betaseron) | $28.3M | 2,983 |
| 355 | Iloperidone (Fanapt) | $28.2M | 13,925 |
| 356 | Aflibercept (Eylea) | $28.0M | 10,899 |
| 357 | Fostemsavir Tromethamine (Rukobia) | $27.8M | 3,094 |
| 358 | Colchicine (Colchicine) | $27.5M | 314,046 |
| 359 | Valsartan/Hydrochlorothiazide (Valsartan-Hydrochlorothiazide) | $27.5M | 510,583 |
| 360 | Ropinirole Hcl (Ropinirole Hcl) | $27.5M | 1,204,903 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology